Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.36 |
| ▸ | F12 | P00748 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7713829 | 1.00 | CLK1 (0.41) | CLK1DYRK1AHTR2AHTR2CHTR2B | |
| SCHEMBL14134266 | 0.86 | LMNA (0.40) | HTR2AHTR2CHTR2BLMNACYP2A6 | |
| SCHEMBL22035513 | 0.85 | CLK1 (0.39) | CLK1DYRK1AHTR2AHTR2CHTR2B | |
| SCHEMBL1102399 | 0.79 | LMNA (0.59) | LMNACYP2A6NPC1RAB9AF12 | |
| SCHEMBL31732807 | 0.79 | LMNA (0.59) | LMNACYP2A6NPC1RAB9AF12 | |
| Iodide SCHEMBL10722209 | 0.78 | LMNA (0.58) | LMNACYP2A6NPC1RAB9AF12 | |
| SCHEMBL18237726 | 0.77 | HTR2A (0.38) | CLK1DYRK1AHTR2AHTR2CHTR2B | |
| SCHEMBL10058353 | 0.76 | ACHE (0.33) | LMNACYP2A6NPC1RAB9A | |
| SCHEMBL19297138 | 0.74 | RPS6KA3 (0.35) | DYRK1ALMNAKDM4EHTTPOLB | |
| SCHEMBL19297137 | 0.74 | RPS6KA3 (0.35) | DYRK1ALMNAKDM4EHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382483-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382483-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB4 | CLK1 2732/4885DYRK1A 1089/4885HTR2A 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.